Relias Media - Continuing Medical Education Publishing

The trusted source for

healthcare information and

CONTINUING EDUCATION.

  • Sign In
  • Sign Out
  • MyAHC
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • My Subscription
      • Subscribe Now
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    Home » Zika-associated vs. Non-Zika Guillain-Barré Syndrome
    ABSTRACT & COMMENTARY

    Zika-associated vs. Non-Zika Guillain-Barré Syndrome

    December 1, 2018
    No Comments
    Reprints
    Facebook Twitter Linkedin Share Share

    Related Articles

    Zika Virus Infection and Guillain-Barré Syndrome: The Evidence Grows

    Zika Virus Infection and Guillain-Barré Syndrome

    Zika Virus Infection and Guillain-Barré Syndrome: The Evidence Grows

    Related Products

    Zika Virus Infection and Guillain-Barré Syndrome: The Evidence Grows

    Zika Virus Infection and Guillain-Barré Syndrome

    Keywords

    zika

    guillain-barré

    By Michael Rubin, MD

    Professor of Clinical Neurology, Weill Cornell Medical College

    Dr. Rubin reports no financial relationships relevant to this field of study.

    SYNOPSIS: Guillain-Barré syndrome associated with Zika virus is similar to non-Zika virus cases in terms of severity of illness and prognosis around long-term recovery and disability.

    SOURCE: Dirlikov E, Major CG, Medina NA, et al. Clinical features of Guillain-Barré syndrome with vs without Zika virus infection, Puerto Rico, 2016. JAMA Neurol 2018;75:1089-1097.

    Transmitted by mosquitoes, Zika virus (ZIKV) is an arthropod-borne virus (arbovirus) that is related to other flaviviruses, including dengue, yellow fever, and West Nile. Approximately 20% of patients experience nonspecific manifestations of infection, including low-grade fever, rash, arthralgias, or conjunctivitis. More serious neurologic complications include congenital microcephaly, encephalitis, meningoencephalitis, transverse myelitis, and Guillain-Barré syndrome (GBS). Can GBS associated with ZIKV be differentiated from GBS that is not associated?

    ZIKV disease was reported by the Department of Health, San Juan, Puerto Rico, in December 2015, with the first case of GBS in a patient with prior ZIKV infection confirmed in January 2016. In February 2016, public health surveillance was implemented to identify cases of GBS prospectively and test patients for ZIKV, dengue virus, and chikungunya virus. In October 2016, GBS case reporting was made compulsory. Between February and April 2017, all 57 nonspecialized hospitals and two rehabilitation centers in Puerto Rico provided lists of patients hospitalized in 2016 with a diagnostic code of GBS in their medical record. Confirmation of the diagnosis of GBS was performed by medical record review and encompassed clinical presentation, electrodiagnostic studies, cerebrospinal fluid analysis, and absence of an alternative neurologic diagnosis. Telephone interviews were conducted six months following illness onset to determine the extent of long-term disability using the modified Rankin scale, Overall Disability Sum score, and Facial Disability Index. A statistical analysis encompassed Pearson χ2 test, Fisher exact test, and χ2 partitioning to compare categorical variables, with the median two-sample test used to compare continuous variables. P < 0.05 was considered statistically significant.

    Among 135 cases of suspected GBS reported by healthcare professionals in 2016, 98 (72.7%) were confirmed GBS, eight (5.9%) suspected GBS, and 29 (21.5%) non-GBS. Among 181 patients identified by diagnostic code, 100 (55.2%) already had been found through passive public health surveillance. Of the remainder, 25 (34.7%) were confirmed GBS cases, four (5.6%) were suspected GBS, and 43 (59.7%) were non-GBS. The researchers identified 123 confirmed GBS cases, of which 68 (55.3%) were male, with an overall median age of 54 years. ZIKV infection was confirmed in 66.4% of those tested (71 of 107).

    Compared to GBS cases without evidence of ZIKV infection, ZIKV GBS cases were of similar age, although they more often were female. Antecedent illness was reported equally in both groups, but antecedent rash and arthralgia were more frequent in the ZIKV GBS group. Duration of hospitalization, medical complications, mortality rate, and frequency of intravenous immunoglobulin administration were similar in both groups, but those with ZIKV more often were admitted to the ICU and required mechanical ventilation, and were more likely to have facial weakness and paresthesiae, dysphagia, and shortness of breath. At clinical nadir, modified Rankin and Hughes Disability scores were comparable, as were median disability scores at six months, although ZIKV GBS patients reported long-term facial difficulties, including abnormal tearing and drinking from a cup, more often.

    COMMENTARY

    First isolated from a febrile macaque monkey in 1948 in the Zika forest of Uganda (hence its name), ZIKV was an unimportant human pathogen until a 2007 outbreak of what initially was thought to be dengue virus on the island of Yap in Micronesia. It turned out to be ZIKV confirmed by reverse transcriptase PCR. GBS cases then were reported in a 2013-2014 outbreak in French Polynesia, and ZIKV became hyperendemic in some South American areas in 2015. Transmitted by the bite of an infected Aedes species mosquito, humans and monkeys appear to be the only viable vertebral hosts for ZIKV, but it also may be transmitted perinatally, presumably through the placenta, as well as by a blood-borne route and via breast milk and semen.

    Post a comment to this article

    Report Abusive Comment

    www.reliasmedia.com

    Neurology Alert

    View PDF
    Neurology Alert (Vol. 38, No. 4) - December 2018
    December 1, 2018

    Table Of Contents

    Comparison of Two Apheresis Techniques for Treating Relapses in Neuromyelitis Optica Spectrum Disorders

    Zika-associated vs. Non-Zika Guillain-Barré Syndrome

    Idiopathic Adult-onset Laryngeal Dystonia

    Are Women More Prone to Brain Injury Than Men When Playing Soccer?

    A Biomarker to Help With Neurologic Prognosis After Cardiac Arrest

    Oral Anticoagulant-associated ICH

    Begin Test

    Buy this Issue/Course

    Financial Disclosure: Neurology Alert’s Editor in Chief Matthew Fink, MD; Peer Reviewer M. Flint Beal, MD; Executive Editor Leslie Coplin; Editor Jonathan Springston; and Editorial Group Manager Terrey L. Hatcher report no financial relationships relevant to this field of study.

    Shop Now: Search Products

    • Subscription Publications
    • Books & Study Guides
    • Webinars
    • Group & Site
      Licenses
    • State CME/CE
      Requirements

    Webinars And Events

    View All Events
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • My Subscription
      • Subscribe Now
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    • Help
    • Search
    • About Us
    • Sign In
    • Register
    Relias Media - Continuing Medical Education Publishing

    The trusted source for

    healthcare information and

    CONTINUING EDUCATION.

    Customer Service

    customerservice@reliasmedia.com

    U.S. and Canada: 1-800-688-2421 x 2

    International +1-404-262-5476 x 2

    Accounts Receivable

    1-800-688-2421 x 3
    ReliasMedia_AR@reliasmedia.com

    Sales

    1-800-688-2421 x 1

    Mailing Address

    • 1010 Sync St., Suite 100
      Morrisville, NC 27560-5468
      USA

    © 2022 Relias. All rights reserved.

    Do Not Sell My Personal Information  Privacy Policy  Terms of Use  Contact Us  Reprints  Group Sales

    For DSR inquiries or complaints, please reach out to Wes Vaux, Data Privacy Officer, DPO@relias.com

    Design, CMS, Hosting & Web Development :: ePublishing